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Mutations of themonocarboxylate transporter 8 gene (MCT8, SLC16A2) cause the Allan-Herndon-
Dudley syndrome, an X-linked syndrome of severe intellectual deficit and neurological impair-
ment. Mct8 transports thyroid hormones (T4 and T3), and the Allan-Herndon-Dudley syndrome is
likely caused by lack of T3 transport to neurons during critical periods of fetal brain development.
To evaluate the role of Mct8 in thyroid hormone action in the fetal brain we administered T4 or
T3 to thyroidectomized pregnant dams treated with methyl-mercapto-imidazol to produce ma-
ternal and fetal hypothyroidism. Gene expression was then measured in the fetal cerebral cortex.
T4 increased Camk4, Sema3c, and Slc7a3 expression, but T3 was without effect. To investigate the
cause for the lack of T3 action we analyzed the expression of organic anion transport polypeptide
(Oatp14, Slco1c1), a T4 transporter, and Mct8 (Slc16a2), a T4 and T3 transporter, by confocal
microscopy. Bothproteinswerepresent in thebrain capillaries forming theblood-brainbarrier and
in the epithelial cells of the choroid plexus forming the blood-cerebrospinal fluid barrier. It is
concluded that T4 fromthematernal compartment influences geneexpression in the fetal cerebral
cortex, possibly after transport via organic anion transporter polypeptide and/or Mct8, and con-
version to T3 in the astrocytes. On the other hand, T3 does not reach the target neurons despite
the presence of Mct8. The data indicate that T4, through local deiodination, provides most T3 in
the fetal rat brain. The role ofMct8 as a T3 transporter in the fetal rat brain is therefore uncertain.
(Endocrinology 152: 1713–1721, 2011)
Thyroid hormones T4 and T3 are important regulatorsof mammalian brain development (1–4). Their effects
are largelymediatedby the controlof gene expressionafter
the binding of the genomically active T3 to nuclear recep-
tors. T3 is secreted by the thyroid gland, but it is also
produced in target tissues by the 5 deiodination of T4, a
reaction catalyzed by type 2 deiodinase (D2) (5, 6). In
some tissues, such as brain, developing cochlea, brown
adipose tissue, and anterior pituitary, D2 plays an impor-
tant role in providing T3 to the target cells. T4 and T3 are
inactivated to rT3 and T2 by type 3 deiodinase (D3),
which in the brain is expressed in neurons.
Cellular uptake of thyroid hormone requires the pres-
ence of plasma membrane transporters of several protein
families (7). Mutations of one of these transporters, the
monocarboxylate transporter 8 (MCT8, SlC16A2) cause
a X-linked syndrome characterized by intellectual and
neurological impairment from early infancy (8–12). In
addition to theplasmamembraneof target cells (13),Mct8
in rodents is expressed in the capillary endothelial cells
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forming the blood-brain barrier (BBB) and in the epithelial
cells lining the choroid plexuses (14). While Mct8 trans-
ports T4 and T3, other transporters are more selective for
T4. This is the case of the organic anion transporter poly-
peptide 14 (Oatp14 in rodents, OATP-F in humans,
SLCO1C1). Oatp14 is also expressed in the brain capil-
laries and the choroid plexus (14, 15).
T3 therefore reaches the brain and the neural target
cells via two routes. One is the direct access of T3 from the
circulation viaMct8-mediated transport through theBBB.
On the other hand, T3 is formed in astroglial cells by
D2-mediated T4 deiodination (16, 17). The T3 formed in
this pathway is then delivered to neurons and other neural
target cells (17). In D2-deficient mice brain T3 concentra-
tions are about half of normal, suggesting that each path-
way contributes similarly to total T3 in the postnatal brain
(18). We have recently shown subtle differences in the
activity of the T3 from the circulation and that generated
locally (19).
The fetal brain seems however to be largely dependent
on T4 deiodination. In the second trimester human fetus
there is a correlation between T3 concentration and D2
activity in several brain regions (20). In rats the adminis-
tration of T4, but not T3, to pregnant dams increases the
concentration of T3 in the brain of hypothyroid fetuses
(21). The latter experiments indicated that the fetal brain
depends critically on T4 for thyroid hormone action after
its conversion toT3.Wehere extend these observations by
showing that exogenously administered T4 to pregnant
dams influences gene expression in the cerebral cortex
of the fetuses, in contrast to T3 which had no effect.
Because the main determinant for T3 entry into the
brain appears to be the presence ofMct8 in the BBB (14,
22–24), we analyzed whether or not Mct8 is expressed
in the fetal rat brain. The data indicate that the fetal
brain responds to the administration of T4, but not to
T3, despite Mct8 expression.
Materials and Methods
Animal handling
Female Wistar rats grown in our animal facilities and weigh-
ing 250–300 g were used. Protocols for animal handling were
approved by the local institutional Animal Care Committee, fol-
lowing the rules of the European Union. Animals were under
temperature- (22 2 C) and light- (12-h light, 12-h dark cycle;
lights on at 0700) controlled conditions and had free access to
food andwater. All surgical interventions were under anesthesia
with amixture of ketamine andmedetomidine as described (25).
To induce maternal hypothyroidism the pregnant dams were
thyroidectomized on embryonic day 10 (E10, the day of appear-
ance of the vaginal plug was E0) sparing the parathyroid glands
(T group). To induce maternal and fetal hypothyroidism, the T
dams were given 0.02% 2-mercapto-1-methylimidazole (MMI,
Sigma Chemical Co., St. Louis, MO) in the drinking water until
E21 (TMgroup). T4 andT3were separately administered toTM
dams from E10 by constant infusion through osmotic pumps
(Alzet 2ML2, delivering 5.0 l/h, www.alzet.com) containing
the hormone dissolved in 50% propylenglycol. The calculated
daily doses infused, at the moment of implantation, were 8 g
T4/100 g bodyweight (BW)or 1.5gT3/100 gBWandwere not
corrected for increasing weight. The dams of the control (C)
group were sham operated and implanted with osmotic pumps
containing solvent (21). To analyze the relative effects of the
maternal and the fetal thyroidal status, the following groups
were compared: Control on E17 and E21 (C17 and C21); thy-
roidectomized dams on E10 and analyzed on E17 (T17); and
thyroidectomyzed and MMI-treated dams from E10 and ana-
lyzed on E21 (TM21).
At the end of the experiment the dams were anesthesized
and perfused as described after collection of blood (21). The
fetuses were bled, separated from the placenta, and placed on
ice. The livers and brains were removed. The brains were
sagittally sectioned in halves. One half of the whole brain was
used for T4 and T3 determinations. From the other half the
cerebral cortices were dissected out for PCR assays. All tissues
were frozen in dry ice after collection. Most assays were done
using five to seven samples of each group. The fetal plasma and
brain samples consisted of pooled material from three fetuses
of each individual litter (21, 26). Fetal livers were processed
individually. Thyroid hormones, TSH measurements, and
real-time PCRwere done as previously described (21, 26) with
TaqMan probes (Applied Biosystems, Foster City, CA). Sig-
nificance of differences between experimental groups was cal-
culated by one-wayANOVAand the Tukey post hoc test using
the GraphPad software (www.graphpad.com).
Immunofluorescence
Brains from E21 fetuses were fixed in 4% paraformalde-
hyde in 0.1 M phosphate buffer (pH 7.4) for 24 h at 4 C. They
were then cryoprotected in 30% sucrose dissolved in 0.1 M
phosphate buffer (pH 7.4) containing 4% paraformaldehyde,
frozen in dry ice, and 15-m slices obtained in a cryostat. The
slices were kept at 70 C until use. For immunofluorescence
the slices were thawed, air-dried, washed in PBS, and incu-
bated in methanol for 5 min at 20 C. After washing in PBS,
the slices were blocked in PBS containing 0.1% triton X-100,
5% newborn goat serum, and 5% horse serum. The primary
antibodies were diluted in the blocking solution, added to the
slices, and incubated 16 h at 4 C. After three washings in PBS,
the secondary antibodies were added and incubated in the
dark for 1 h at room temperature. The slices were then washed
in PBS and incubated with 4,6-diamidino-2-phenylindole
(DAPI), 0.1 g/ml in PBS. Rabbit antibodies against Mct8
(XE045) and Oatp14 N terminus (XE066) were a generous
gift of Dr. Lori Roberts (Xenoport, Santa Clara, CA) (14) and
were used at 1:300 dilution. Goat anti-Glut1 (N-20, ref sc-
1603) was from Santa Cruz Biotechnology (Santa Cruz, CA)
and was used at 1:100 dilution. The secondary antibodies
were donkey antigoat Alexa 488 (green) and goat antirabbit
Alexa 546 (red) and were used at 1:2000 dilution. Omitting
the first antibodies in the incubation reaction gave no signal.
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Results
Our first goal was to analyze the relative activities of in
vivo administered T4 and T3 on the fetal cerebral cortex.
Instead of administering the hormones directly to the hy-
pothyroid fetuses, they were given via subcutaneous infu-
sion to pregnant dams. The dams had been previously
thyroidectomized and treated with MMI to produce ma-
ternal and fetal hypothyroidism.
The outcome of treatment was checked by TSH and
thyroid hormone measurements in the dams and fetuses
(Fig. 1). The following groups were compared: control
group (C) (i.e., euthyroid dams and fetuses), thyroidecto-
mized dams (T) (i.e., hypothyroid dams and euthyroid
fetuses), thyroidectomized and MMI-treated dams (TM)
(i.e., hypothyroid dams and fetuses), TM dams treated
with T4 (TMT4), and TM dams treated with T3
(TMT3). The T andTMdams had decreased circulating
T4 and T3 and increased TSH. T4 treatment increased
both T4 and T3. T3 treatment increased T3 to a similar
level to that attained by T4 treatment. TSH was normal-
izedbyeither treatment. FetalTSH,on theotherhand,was
normal in the T group and increased in the TM group. T4
administration to the TM dams normalized fetal TSH,
while T3 treatment had a modest effect.
In the liver, MMI treatment (TM dams) decreased T4
and T3 (Fig. 1). In fetuses from thyroidectomized dams,
T4 remained at normal levels, and T3 was decreased by
about 50%. A reduction of thyroid hormones in tissues of
fetuses from thyroidectomized dams has been previously
reported in some studies (27). T4 treatment increased fetal
liver T4 and T3, without reaching normal control values.
T3 treatment had no effect on liver T4 and increased T3 to
the same level as after T4 treatment. The data indicated
that similar amounts of T3 were available to the hypo-
thyroid fetuses after T4 or T3 administration to the dams.
In the fetal brain, thyroidectomy caused a small de-
crease in T4, with no changes in T3, whereas additional
treatment with MMI (TM dams) decreased T4 and T3 to
around 30 and 10%of control concentrations. Treatment
with T4 increased brain T4 without reaching C or T val-
ues. T4 treatment, however, increased T3 to the same val-
ues as C or T fetuses. T3 concentrations were also in-
creased by T3 treatment but remained at about half the
level reached with T4 treatment.
To analyze the relative activity of T4 and T3 treat-
ment in the fetal brain we used as end points the ex-
pression of three of the genes recently shown to be al-
tered by fetal hypothyroidism in the cerebral cortex and
induced by T3 after addition to primary cortex neurons
in culture (21, 26): Camk4 (Ca2 and calmodulin-de-
pendent protein kinase 4), Slc7a3 (encoding the cationic
exchanger Solute carrier family 7 member 3), and
Sema3c (or Semaphorin 3C).
In agreement with previous data (26) we show in Fig. 2
(left panels) that these genes are regulated primarily by the
fetal thyroid hormones. On E17 (i.e., before onset of fetal
thyroid secretion), there was no effect of maternal thy-
roidectomy (T17 vs. C17) on the expression of any of the
genes analyzed. From E17 to E21 Camk4 and Sema3c
FIG. 1. TSH and thyroid hormones in dams and E21 fetuses. C,
control dams; T, thyroidectomized dams; TM, thyroidectomized dams
treated with MMI; TMT4, TM dams infused with 8 g T4/100 g BW/
d; TMT3, TM dams infused with 1.5 g T3/100 g BW/d. The number
of samples was between five and seven in each group for plasma, and
13–15 for liver. Data are means  SE. One-way ANOVA for maternal
TSH, F (4, 25)  49.15, P  0.0001; fetal TSH, F (4, 24)  150.1, P 
0.0001; maternal plasma T4, F (4, 22)  16.44, P  0.0001; maternal
plasma T3, F (4, 22)  82.67, P  0.0001; fetal liver T4, F (4, 61) 
46.3, P  0.0001; fetal liver T3, F (4, 61)  84.26, P  0.0001; fetal
brain T4, F (4, 45)  66.31, P  0.0001; fetal brain T3, F (4, 37) 
57.21, P  0.0001. Comparisons are as follows: different from C (a),
different from T (b), and different from TM (c).
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increased in control animals (C17 vs. C21). This increase
can be attributed to the onset of function and progressive
activity of the fetal thyroid gland taking place during this
period. In E21 fetuses in which the thyroid gland was
blocked by treatment with MMI (TM21 group) Camk4
and Sema3c remained at the E17 level. In contrast, Slc7a3
decreased slightly in control animals fromE17 toE21, and
hypothyroidism induced a greater decrease. These results
show that fetal thyroid hormones regulate developmental
changes in the expression of these genes, allowing an in-
crease in the expression of Camk4 and Sema3c and a fine
adjustment of Slc7a3.
The right panels of Fig. 2 show the expression of these
genes on E21 after hormone administration to the dams.
Maternal thyroidectomy did not change the expression of
the genes, in agreement with the primary role of the fetal
hormones. Suppression of fetal thyroid secretion with
MMI treatment decreased the expression of the three
genes. Treatment with T4 was effective in normalizing
gene expression, but T3 was without effect.
It is thought that D3 activity, which is high in fetal
tissues, is an important modulator of T3 action in the
developing brain (28, 29). Therefore we checked whether
Dio3 expression in the cerebral cortex changed with the
different treatments (Fig. 3). Although the mean levels af-
ter T3 treatment were higher, the changes were not
significant.
Thyroid hormone action requires the presence of trans-
porters in the plasma membrane of target cells (7). In the
brain, transporters are required for T4 and T3 to cross the
BBB (14, 22). We analyzed the expression of Mct8,
Oatp14, Lat2 (Slc7a6), and Mct10 (Slc16a10) (Fig. 4).
The data were normalized to the value obtained for Mct8
on E21 after correcting for 18S RNA. Mct8 mRNA con-
tent was higher during the prenatal stages than at post-
natal d 15.Oatp14, Lat2, andMct10were also expressed
in the fetal cortex and increased during the postnatal pe-
riod. The amounts of Mct10 mRNA were extremely low
in comparison with the other transporters. As a reference
for gross cellular changes taking place in the cortex from
the fetal to the postnatal period, we measured the expres-
sion of the glucose transporter Glut-1, expressed in the
capillary endothelia, and the intermediate filament glial
fibrillary acidic protein, Gfap, expressed in astrocytes.
Glut-1 mRNA decreased slightly on E21 and then in-
creased on P15. Gfap mRNA had a large increase on P15,
reflecting the accumulation of astroglia taking place
postnatally.
FIG. 3. Real-time PCR determination of Dio3 transcript levels in the
fetal cerebral cortex on E21. The experimental groups are as in Fig. 1.
Changes among the groups were not significant: F (4, 23)  2.349,
P  0.084.
FIG. 2. Real-time PCR determination of transcript levels in the fetal
cerebral cortex on E17 and E21. The experimental groups are as in Fig.
1. Left, Effect of maternal hypothyroidism (T) on E17 and of maternal
and fetal hypothyroidism TM on E21. The number of samples was five
in each group. Data are means  SE. One-way ANOVA for Camk4, F
(3, 16)  32.83, P  0.0011; for Sema3c, F (3, 16)  31.18, P 
0.0001; and for Slc7a3, F (3, 16)  30.69, P  0.0049. Right, Effect of
T4 and T3 infusion on transcript levels on E21. The number of samples
was six in each group. Data are means  SE. One-way ANOVA for
Camk4, F (4, 25)  6.40, P  0.0011; for Sema3c, F (4, 25)  9.20,
P  0.0001; and for Slc7a3, F (4, 25)  4.86, P  0.0049.
Comparisons are as follows: different from C (a), different from T (b),
and different from TM (c).
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To analyze the expression and distribution of theMct8
and Oatp14 proteins we used immunofluorescence and
confocal microscopy. (Figs. 5 and 6). Figure 5 shows that
Mct8 andOatp14were present in the cerebral cortex, and
their expression was coincident with that of Glut-1. Both
transporters were also present in the choroid plexus (Fig.
6). Oatp14was observed in the epithelial cells forming the
blood-cerebrospinal fluid barrier. The proteinwasmainly
present in the apical and lateral borders, but it was also
observed in the basal membrane of many cells. There was
also some staining for Oatp14 inside the plexus. Interest-
ingly, Oatp14 was also present in the ependymal cells lin-
ing the ventriclewalls.Mct8was present exclusively in the
epithelial cells, mostly in the apical side, but also in the
basal side of some cells. Expression in the choroid plexus
exceeded by far that of the capillaries, so that the images
had to be overexposed to observe the immunochemical
signal from the vessels and from the choroid plexus in the
same picture (Fig. 6C).
Discussion
Calvo et al. (21) administered increasing doses of T4orT3
to MMI-treated pregnant dams, a model of maternal and
fetal hypothyroidism similar to the one used in the present
work. They found that T4 administration resulted in the
presence ofT3 in the fetal brain andprevented the increase
of fetal TSH and fetal brain D2 activity induced by MMI
treatment. In contrast, administration of T3 in compara-
tively higher doses didnot increase brainT3concentration
over hypothyroid levels and had no effect on the fetal TSH
or D2. The reason for the differences between T4 and T3
treatment was not the lack of placental transport, because
both T4 and T3 were present in fetal plasma and tissues
other than thebrain after their administration to thedams.
It was therefore proposed that the fetal brainwas crucially
dependent on T4. The lack of suitable T3 target genes
precluded the demonstration that also systemic T4, but
not T3, was active on fetal brain gene targets.
On the other hand, we have recently shown that fetal
hypothyroidism affects cerebral cortex gene expression
(19). Several of the genes affected by hypothyroidismwere
also increased by T3 in neuronal primary cultures, indi-
cating a direct cellular response to T3. In the present work
we have analyzed the expression of three of these genes to
explore whether thyroid hormones from the maternal
compartmentwere able to influence gene expression in the
fetal cerebral cortex. The experimental set up was similar
to that of Calvo et al. (21) and was based upon the use of
thyroidectomy to achieve isolated maternal hypothyroid-
ism and additional MMI treatment to
inducematernal and fetal hypothyroid-
ism. In agreement with the experimen-
tal set up, TSH determinations showed
that thyroidectomy increased TSH in
the maternal but not in the fetal blood,
whereas MMI treatment increased
TSH in both dams and fetuses.
T3 treatment suppressed maternal
TSH but had little effect on fetal TSH.
In contrast, T4 treatment was effective
onboth thematernal and the fetal TSH.
The mechanism is not known, but the
result agrees with previous work show-
ing effects of exogenousT3on fetalGH
but not on fetal TSH (30). As in previ-
ous studies, the different effects of T4
FIG. 4. Transcript levels of the thyroid hormone transporters Mct8,
Oatp14, Lat-2, and Mct10, Glut-1, and the Gfap in the cerebral cortex
on E17, E21, and P15. Data are means  SE. One-way ANOVA for
Mct8, F (2, 12)  91.5, P  0.0001; Oatp14, F (2, 12)  218.4, P 
0.0001; Lat2, F (2, 12)  220.5, P  0.0001; Glut-1, F (2, 12) 
24.02, P  0.0001; Gfap, F (2, 12)  345.4, P  0.0001; Mct10, F (2,
11)  78.57, P  0.0001. Comparisons are as follows: different from
E17 (a), different from E21 (b).
FIG. 5. Confocal microscopy for Mct8 and Oatp14 in the rat fetal cerebral cortex. A, Mct8. B,
Glut-1. C, Merge and DAPI staining. D, Oatp14. E, Glut-1. F, Merge and DAPI staining. Mct8
and Oatp-14 colocalize with Glut-1, a marker of brain vascular endothelial cells. Scale bars, 50 m.
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and T3 could not be explained by restricted T3 transport
at the placental level. In fact, after T4 or T3 treatment
similar amounts of T3 were found in fetal liver, expected
to reflect circulating blood levels. Regulation of fetal TSH
is independent onhypothalamicTRHuntilwell after birth
(31–33). Also, from the experiments cited above (30), the
control by thyroid hormone is probably exerted at the
pituitary level. It is likely that transporters play a role (34,
35), for example by facilitating the selective uptake of T4
into the D2-expressing cells in the fetal pituitary.
This experimental model allowed us to analyze the ef-
fect of the hormones from the maternal compartment on
gene expression in the fetal cortex. The expression pat-
terns of these genes are related to the onset of fetal thyroid
gland function and, in agreement with previous data (26),
they were not affected by isolated maternal hypothyroid-
ism. Therefore, these genes are primarily regulated by the
fetal thyroid hormones, without any direct or indirect ef-
fects of maternal hypothyroidism. These results allow us
to discard that the effect of treatment on gene responses
are attributable to abeneficial effect on the general thyroid
status of themother, or the fetus, rather than adirect effect
on the fetal brain.
Gene expression in thehypothyroid fetal brainwasnor-
malized by T4, but not by T3, administration to the preg-
nant dams. The effect of T4 is most likely attributable to
the T3 generated locally in the brain from the T4 precur-
sor, because D2 activity increases in brain in the last days
of gestation (36). Calvo et al. (21) observed that after
administration of T4 to the pregnant dams, T3 accumu-
lated in the fetal brain, but not after administration of T3.
Although we found that T3 increased in the fetal brain
after T3 administration, it was not enough to stimulate
gene expression. The concentrations of T3 attained by T4
treatment were higher and resulted in normalization of
gene expression. The reason for the quantitative differ-
ences between our results and those fromCalvo et al. (21)
are not clear to us, but the final conclusion, that the fetal
brain is dependent on T4, and little or nothing on T3,
remains the same.
Interestingly, the defective T3 accumulation and action
in the fetal brain resembles the situation of mice deprived
of the thyroid hormone transporter Mct8 (Mct8-/y), in
which brain gene expression is less sensitive to exogenous
T3 (22) and relies on D2-mediated T4 to T3 conversion
(19). For this reasonwe analyzed the expressionof thyroid
hormone transporters in the fetal cortex by quantitative
PCR and immunofluorescence. Mct8 has similar trans-
port activities for T4 and T3, and also transports rT3 and
T2.Oatp14 has a transport activity several fold higher for
T4 and rT3 than for T3 (15, 37). Lat-2 was also studied
because of its possible importance in the human fetal brain
(38). By quantitative PCR we show that expression of
Mct8 is more abundant in fetal cortex than in postnatal
cortex. In humans Mct8 is also more abundant during
early brain development (39). Lat-2 and Oatp14 were
more abundant in the postnatal than the fetal cortex. By
confocal microscopy Mct8 and Oatp14 proteins were
present in the cerebral cortex and in the choroid plexus, in
similar patterns as described by Roberts et al. (14). The
presence of Oatp14 explains the transport of T4, but the
restrictedT3 transport cannotbe explained in thepresence
of Mct8 expression.
As reported previously by Roberts et al. (14), Oatp14
is present in the abluminal side of endothelial capillary
cells and overlaps partially with aquaporin-4, a marker of
astrocytic end-feet. The increased concentration of
Oatp14 mRNA during the postnatal period, in parallel to
the increased abundance of astrocytes as shown by Gfap,
FIG. 6. Confocal microscopy for Oatp14 and Mct8 in the rat fetal
choroid plexus of the lateral ventricle. Immunofluorescence for Oatp14
or Mct8 (red) combined with Glut-1 (red) and DAPI (blue). A, Oatp14 is
expressed in the epithelial cells forming the blood-cerebrospinal fluid
barrier (arrows) and in the ependymal layer lining the ventricle wall
(arrowheads). B, Mct8 is expressed in the epithelial cells of choroid
plexus and is absent from the ventricular wall. C, Overexposure of
Mct8 immunofluorescence images to show Mct8 expression in the
vessels in the same picture. Scale bars, 25 m (A and B) or 50 m (C).
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agreeswith the astrocytic expression.Therefore, it is likely
that T4 from the circulation is transported via Oatp14
directly to the astrocytes where it undergoes D2-mediated
conversion toT3.Mct8 did not overlapwith aquaporin-4,
suggesting that circulating T4 and T3 may be delivered to
the extracellular fluid after Mct8-mediated transport.
Similarly, blood glucose can access the neurons directly
after transport to the extracellular fluid, or after transport
into the astrocytes and conversion to lactate (40).
Once delivered to the extracellular fluid T4 and T3will
have direct access to neurons and serve as substrates for
D3 (41). D3 is abundantly expressed in fetal brain and
other tissues and decreases rapidly during the postnatal
period (42–44). Its subcellular localization allows rapid
degradation of T4 and T3 after they enter the D3-express-
ing cells (5). Therefore, D3 activity is another player in
determining the relative contributions of systemic T3 vs.
the T3 produced locally from T4. It is particularly impor-
tant during development (28, 29) when D3 deletion in-
creases target gene responses toT3 (45). In thehuman fetal
brain, D3 activity in the cerebellum prevents the accumu-
lation of T3 during mid-gestation, whereas in the cerebral
cortex the increased T3 concentration during the second
trimester is parallel to increasedD2activity (20).Given the
presence of significant D2 activity in the rat fetal brain
(36), which explains the present and previous data (21),
most thyroid hormone action in the fetal brain would be
attributable to the T3 of local origin (Fig. 7). As D3 ex-
pression decreases during further development, the con-
tribution of systemic T3 would increase to reach the ap-
proximate contribution of about 50% to the T3 present in
the brain (18). An additional possibility is that D3 is also
expressed in the vascular endothelial cells, as shown pre-
viously in hemangiomas (46) and in the fetal microvessels
of the placenta (47), but this would not explain a T3
selectivity.
The mechanism of transfer of T3 from the astrocytes
to the neurons is not clear. Our previous data showed
that Mct8 deficiency did not prevent the effect of T4
administration on the expression of target genes, de-
spite the impairment of the effect of T3 (22). We also
demonstrated that gene expression in the cerebral cor-
tex of Mct8-deficient mice was compensated by D2 ac-
tivity (19). Therefore, other mechanisms different from
Mct8-mediated transport would supply T3 from the
astrocytes to the neurons, at least in postnatal stages.
Data extracted from the genomic database of mouse
brain cells by Cahoy et al. (48) indicate that astrocytes
express predominantly Oatp14 and much lower
amounts of Lat-1 and Mct8 (Supplemental Fig. 1 pub-
lished on The Endocrine Society’s Journals Online web
site at http://endo.endojournals.org/). Neurons express
Lat-1, Lat-2, and Mct8. Combinatorial expression of
these transporters would allow the transfer of T3 from
the astrocytes to different cellular subsets.We could not
detect the Mct8 protein in the brain parenchyma in
agreementwithRoberts et al. (14).However thismay be
attributable to lack of resolution, and it could be that
during fetal stages the expression of Mct8 in discrete
cellular subsets is more important, relative to other
transporters, for the uptake of T3 produced in the as-
trocytes. It would therefore be required to analyze the
impact of Mct8 deletion on gene expression in the fetal
mouse brain.
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FIG. 7. Cartoon depicting the hypothetical fate of T4 and T3 in the
fetal brain. T4 from the circulation crosses the BBB and reaches the
astrocytes through Oatp14. Once in the astrocytes it is converted to
T3 by D2 and is released to the neurons. T4 and T3 cross the BBB
through Mct8 and are delivered to the interstitial fluid. It is possible
that the topology of D3 in the neuronal membrane allows for easy
inactivation of T4 and T3 with the production of rT3 and T2, which
would then be released back to the circulation. Oatp14 and Mct8
are represented in black boxes. Other possible transporters are
represented in gray boxes.
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